Geroprotectors as a novel therapeutic strategy for COPD, an accelerating aging disease

International Journal of COPD

Volumn 7, Issue , 2012, Pages 641-652

  Ito, Kazuhiro ^a   Colley, Thomas ^a   Mercado, Nicolas ^a  

^a NATIONAL HEART AND LUNG INSTITUTE   (United Kingdom)

Author keywords

COPD; Geroprotector; Lung function; Oxidative stress; Premature aging; Sirtuin

Indexed keywords

2 MORPHOLINO 8 PHENYLCHROMONE; CIGARETTE SMOKE; CORTICOSTEROID; DNA; ENZYME ACTIVATOR; GEROPROTECTOR; MAMMALIAN TARGET OF RAPAMYCIN INHIBITOR; MELATONIN; METFORMIN; NRF2 ACTIVATOR; PHOSPHATIDYLINOSITOL 3 KINASE INHIBITOR; PLACEBO; RAPAMYCIN; REACTIVE OXYGEN METABOLITE; RESPIRATORY TRACT AGENT; RESVERATROL; SIRTUIN ACTIVATOR; SOMATOMEDIN C; SRT 2172; SULFORAPHANE; THEOPHYLLINE; UNCLASSIFIED DRUG; ANTIOXIDANT; ENZYME INHIBITOR; PROTECTIVE AGENT;

AGING; ANTIINFLAMMATORY ACTIVITY; ANTIOXIDANT ACTIVITY; ANTIPROLIFERATIVE ACTIVITY; ASTHMA; CALORIC RESTRICTION; CELL AGING; CELL DIVISION; CHRONIC OBSTRUCTIVE LUNG DISEASE; DIABETES MELLITUS; DNA DAMAGE; DNA REPAIR; DRUG EFFICACY; DRUG MECHANISM; EXERCISE TOLERANCE; GRAFT REJECTION; HOMEOSTASIS; HUMAN; INNATE IMMUNITY; LIFE EXTENSION; LOW DRUG DOSE; LUNG FUNCTION; NONHUMAN; OVARY POLYCYSTIC DISEASE; OXIDATIVE STRESS; PATHOGENESIS; PREMATURE AGING; PROTEIN EXPRESSION; RANDOMIZED CONTROLLED TRIAL (TOPIC); REVIEW; SENESCENCE; SIGNAL TRANSDUCTION; TELOMERE SHORTENING; AGE; AGED; ANIMAL; DRUG EFFECT; IMMUNOLOGY; LUNG; METABOLISM; PATHOLOGY; PATHOPHYSIOLOGY; RISK FACTOR;

AGE FACTORS; AGED; AGED, 80 AND OVER; AGING; ANIMALS; ANTIOXIDANTS; CALORIC RESTRICTION; CELL AGING; ENZYME INHIBITORS; HUMANS; LUNG; OXIDATIVE STRESS; PROTECTIVE AGENTS; PULMONARY DISEASE, CHRONIC OBSTRUCTIVE; RISK FACTORS; SIGNAL TRANSDUCTION;

EID: 84872231816     PISSN: 11769106     EISSN: 11782005     Source Type: Journal    
DOI: 10.2147/COPD.S28250     Document Type: Review

References (101)

1. United Nation. World Population to reach 10 billion by 2100 if Fertility in all Countries Converges to Replacement Level. UNITED NATIONS PRESS RELEASE. 3-5-2011. Ref Type: Abstract.
2. Buist AS, McBurnie MA, Vollmer WM, et al. International variation in the prevalence of COPD (the BOLD Study): a population-based prevalence study. Lancet. September 1, 2007;370(9589):741-750.
3. Menn P, Heinrich J, Huber RM, et al. Direct medical costs of COPD - An excess cost approach based on two population-based studies. Respir Med. Apr 2012;106(4):540-548.
4. Hogg JC, Timens W. The pathology of chronic obstructive pulmonary disease. Annu Rev Pathol. 2009;4:435-459.
5. Ito K, Barnes PJ. COPD as a disease of accelerated lung aging. Chest. Jan 2009;135(1):173-180.
6. Lee J, Sandford A, Man P, Sin DD. Is the aging process accelerated in chronic obstructive pulmonary disease? Curr Opin Pulm Med. Mar 2011;17(2):90-97.
7. Fletcher C, Peto R. The natural history of chronic airflow obstruction. Br Med J. June 25, 1977;1(6077):1645-1648.
8. Tantucci C, Modina D. Lung function decline in COPD. Int J Chron Obstruct Pulmon Dis. 2012;7:95-99.
9. Janssens JP, Pache JC, Nicod LP. Physiological changes in respira-tory function associated with ageing. Eur Respir J. Jan 1999;13(1): 197-205.
10. Chan ED, Welsh CH. Geriatric respiratory medicine. Chest. Dec 1998; 114(6):1704-1733.
11. Tolep K, Kelsen SG. Effect of aging on respiratory skeletal muscles. Clin Chest Med. Sep 1993;14(3):363-378.
12. Lee N, Shin MS, Kang I. T-cell biology in aging, with a focus on lung disease. J Gerontol A Biol Sci Med Sci. Mar 2012;67(3):254-263.
13. Meyer KC, Rosenthal NS, Soergel P, Peterson K. Neutrophils and low-grade inflammation in the seemingly normal aging human lung. Mech Ageing Dev. August 14, 1998;104(2):169-181.
14. Kirkwood TB. Understanding the odd science of aging. Cell. February 25, 2005;120(4):437-447.
15. Harman D. Free radical theory of aging: an update: increasing the functional life span. Ann N Y Acad Sci. May 2006;1067:10-21.
16. Promislow DE. DNA repair and the evolution of longevity: a critical analysis. J Theor Biol. October 7, 1994;170(3):291-300.
17. Vogel H, Lim DS, Karsenty G, Finegold M, Hasty P. Deletion of Ku86 causes early onset of senescence in mice. Proc Natl Acad Sci U S A. September 14, 1999;96(19):10770-10775.
18. Rahman I, Adcock IM. Oxidative stress and redox regulation of lung inflammation in COPD. Eur Respir J. Jul 2006;28(1):219-242.
19. Fulop T, Larbi A, Douziech N, Levesque I, Varin A, Herbein G. Cytokine receptor signalling and aging. Mech Ageing Dev. Jun 2006; 127(6):526-537.
20. Chung HY, Sung B, Jung KJ, Zou Y, Yu BP. The molecular inflammatory process in aging. Antioxid Redox Signal. Mar 2006;8(3-4):572-581.
21. Ito K. Does lung aging have an impact on chronic obstructive pulmonary disease? J Organ Dysfunction. January 22, 2007;3(4):204-220.
22. von Zglinicki T. Oxidative stress shortens telomeres. Trends Biochem Sci. Jul 2002;27(7):339-344.
23. Grubisha O, Smith BC, Denu JM. Small molecule regulation of Sir2 protein deacetylases. FEBS J. Sep 2005;272(18):4607-4616.
24. Rahman S, Islam R. Mammalian Sirt1: insights on its biological functions. Cell Commun Signal. 2011;9:11.
25. Mostoslavsky R, Chua KF, Lombard DB, et al. Genomic instability and aging-like phenotype in the absence of mammalian SIRT6. Cell. January 27, 2006;124(2):315-329.
26. Harms KL, Chen X. Histone deacetylase 2 modulates p53 transcriptional activities through regulation of p53-DNA binding activity. Cancer Res. April 1, 2007;67(7):3145-3152.
27. Kaestner KH, Knochel W, Martinez DE. Unified nomenclature for the winged helix/forkhead transcription factors. Genes Dev. January 15, 2000;14(2):142-146.
28. Hwang JW, Rajendrasozhan S, Yao H, et al. FOXO3 deficiency leads to increased susceptibility to cigarette smoke-induced inflammation, airspace enlargement, and chronic obstructive pulmonary disease. J Immunol. July 15, 2011;187(2):987-998.
29. Suga T, Kurabayashi M, Sando Y, et al. Disruption of the klotho gene causes pulmonary emphysema in mice. Defect in maintenance of pulmonary integrity during postnatal life. Am J Respir Cell Mol Biol. Jan 2000;22(1):26-33.
30. Fukuchi Y. The aging lung and chronic obstructive pulmonary disease: similarity and difference. Proc Am Thorac Soc. December 1, 2009;6(7): 570-572.
31. Maruyama N, Ishigami A, Kuramoto M, et al. Senescence marker protein-30 knockout mouse as an aging model. Ann N Y Acad Sci. Jun 2004;1019:383-387.
32. Sato T, Seyama K, Sato Y, et al. Senescence marker protein-30 protects mice lungs from oxidative stress, aging, and smoking. Am J Respir Crit Care Med. September 1, 2006;174(5):530-537.
33. Koike K, Kondo Y, Sekiya M, et al. Complete lack of vitamin C intake generates pulmonary emphysema in senescence marker protein-30 knockout mice. Am J Physiol Lung Cell Mol Physiol. Jun 2010;298(6): L784-L792.
34. Vestbo J, Edwards LD, Scanlon PD, et al. Changes in forced expiratory volume in 1 second over time in COPD. N Engl J Med. September 29, 2011;365(13):1184-1192.
35. Patel BD, Loo WJ, Tasker AD, et al. Smoking related COPD and facial wrinkling: is there a common susceptibility? Thorax. Jul 2006;61(7): 568-571.
36. Aoshiba K, Nagai A. Senescence hypothesis for the pathogenetic mechanism of chronic obstructive pulmonary disease. Proc Am Thorac Soc. December 1, 2009;6(7):596-601.
37. Sharma G, Hanania NA, Shim YM. The aging immune system and its relationship to the development of chronic obstructive pulmonary disease. Proc Am Thorac Soc. December 1, 2009;6(7):573-580.
38. Tsuji T, Aoshiba K, Nagai A. Alveolar cell senescence in patients with pulmonary emphysema. Am J Respir Crit Care Med. October 15, 2006; 174(8):886-893.
39. MacNee W. Oxidants/antioxidants and chronic obstructive pulmonary disease: pathogenesis to therapy. Novartis Found Symp. 2001;234: 169-185.
40. Sekine Y, Katsura H, Koh E, Hiroshima K, Fujisawa T. Early detec-tion of COPD is important for lung cancer surveillance. Eur Respir J. May 2012;39(5):1230-1240.
41. de Torres JP, Marin JM, Casanova C, et al. Lung cancer in patients with chronic obstructive pulmonary disease - incidence and predict-ing factors. Am J Respir Crit Care Med. October 15, 2011;184(8): 913-919.
42. Nadeem A, Raj HG, Chhabra SK. Increased oxidative stress and altered levels of antioxidants in chronic obstructive pulmonary disease. Inflammation. Feb 2005;29(1):23-32.
43. Kirkil G, Hamdi MM, Seckin D, Sahin K, Kucuk O. Antioxidant effect of zinc picolinate in patients with chronic obstructive pulmonary disease. Respir Med. Jun 2008;102(6):840-844.
44. Malhotra D, Thimmulappa R, Navas-Acien A, et al. Decline in NRF2-regulated antioxidants in chronic obstructive pulmonary disease lungs due to loss of its positive regulator, DJ-1. Am J Respir Crit Care Med. September 15, 2008;178(6):592-604.
45. Nakamaru Y, Vuppusetty C, Wada H, et al. A protein deacetylase SIRT1 is a negative regulator of metalloproteinase-9. FASEB J. Sep 2009; 23(9):2810-2819.
46. Rajendrasozhan S, Yang SR, Kinnula VL, Rahman I. SIRT1, an anti-inflammatory and antiaging protein, is decreased in lungs of patients with chronic obstructive pulmonary disease. Am J Respir Crit Care Med. April 15, 2008;177(8):861-870.
47. Ito K, Ito M, Elliott WM, et al. Decreased histone deacetylase activity in chronic obstructive pulmonary disease. N Engl J Med. May 12, 2005; 352(19):1967-1976.
48. Ito K, Yamamura S, Essilfie-Quaye S, et al. Histone deacetylase 2- mediated deacetylation of the glucocorticoid receptor enables NF-kappaB suppression. J Exp Med. January 23, 2006;203(1):7-13.
49. Tsuji T, Aoshiba K, Nagai A. Alveolar cell senescence in patients with pulmonary emphysema. Am J Respir Crit Care Med. October 15, 2006; 174(8):886-893.
50. Savale L, Chaouat A, Bastuji-Garin S, et al. Shortened telomeres in circulating leukocytes of patients with chronic obstructive pulmonary disease. Am J Respir Crit Care Med. April 1, 2009;179(7):566-571.
51. Morla M, Busquets X, Pons J, Sauleda J, MacNee W, Agusti AG. Telomere shortening in smokers with and without COPD. Eur Respir J. Mar 2006;27(3):525-528.
52. Muller KC, Welker L, Paasch K, et al. Lung fibroblasts from patients with emphysema show markers of senescence in vitro. Respir Res. 2006;7:32.
53. Holzenberger M. Igf-I signaling and effects on longevity. Nestle Nutr Workshop Ser Pediatr Program. 2011;68:237-245.
54. Barbieri M, Bonafe M, Franceschi C, Paolisso G. Insulin/IGF-I- signaling pathway: an evolutionarily conserved mechanism of longevity from yeast to humans. Am J Physiol Endocrinol Metab. Nov 2003; 285(5):E1064-E1071.
55. Kaletsky R, Murphy CT. The role of insulin/IGF-like signaling in C. elegans longevity and aging. Dis Model Mech. Jul 2010;3(7-8): 415-419.
56. Vanfleteren JR, Braeckman BP. Mechanisms of life span determina-tion in Caenorhabditis elegans. Neurobiol Aging. Sep 1999;20(5): 487-502.
57. Honda Y, Honda S. The daf-2 gene network for longevity regulates oxi-dative stress resistance and Mn-superoxide dismutase gene expression in Caenorhabditis elegans. FASEB J. Aug 1999;13(11):1385-1393.
58. Scott BA, Avidan MS, Crowder CM. Regulation of hypoxic death in C. elegans by the insulin/IGF receptor homolog DAF-2. Science. June 28, 2002;296(5577):2388-2391.
59. Garsin DA, Villanueva JM, Begun J, et al. Long-lived C. elegans daf-2 mutants are resistant to bacterial pathogens. Science. June 20, 2003;300(5627):1921.
60. Tullet JM, Hertweck M, An JH, et al. Direct inhibition of the longevity-promoting factor SKN-1 by insulin-like signaling in C. elegans. Cell. March 21, 2008;132(6):1025-1038.
61. Hsieh CC, DeFord JH, Flurkey K, Harrison DE, Papaconstantinou J. Implications for the insulin signaling pathway in Snell dwarf mouse longevity: a similarity with the C. elegans longevity paradigm. Mech Ageing Dev. May 2002;123(9):1229-1244.
62. Ziv E, Hu D. Genetic variation in insulin/IGF-1 signaling pathways and longevity. Ageing Res Rev. Apr 2011;10(2):201-204.
63. Mercado N, Thimmulappa R, Thomas CM, et al. Decreased histone deacetylase 2 impairs Nrf2 activation by oxidative stress. Biochem Biophys Res Commun. March 11, 2011;406(2):292-298.
64. Osoata GO, Yamamura S, Ito M, et al. Nitration of distinct tyrosine residues causes inactivation of histone deacetylase 2. Biochem Biophys Res Commun. July 3, 2009;384(3):366-371.
65. Izmaylov DM, Obukhova LK. Geroprotector effectiveness of melatonin: investigation of lifespan of Drosophila melanogaster. Mech Ageing Dev. January 15, 1999;106(3):233-240.
66. Bulterijs S. Metformin as a geroprotector. Rejuvenation Res. Oct 2011; 14(5):469-482.
67. Anisimov VN, Berstein LM, Popovich IG, et al. If started early in life, metformin treatment increases life span and postpones tumors in female SHR mice. Aging (Albany NY). Feb 2011;3(2):148-157.
68. Anisimov VN, Berstein LM, Egormin PA, et al. Effect of metformin on life span and on the development of spontaneous mammary tumors in HER-2/neu transgenic mice. Exp Gerontol. Aug 2005;40(8-9): 685-693.
69. Wang S, Song P, Zou MH. AMP-activated protein kinase, stress responses and cardiovascular diseases. Clin Sci (Lond). June 1, 2012; 122(12):555-573.
70. Canto C, Gerhart-Hines Z, Feige JN, et al. AMPK regulates energy expenditure by modulating NAD+ metabolism and SIRT1 activity. Nature. April 23, 2009;458(7241):1056-1060.
71. Dowling RJ, Zakikhani M, Fantus IG, Pollak M, Sonenberg N. Metformin inhibits mammalian target of rapamycin-dependent trans-lation initiation in breast cancer cells. Cancer Res. November 15, 2007;67(22): 10804-10812.
72. Memmott RM, Mercado JR, Maier CR, Kawabata S, Fox SD, Dennis PA. Metformin prevents tobacco carcinogen - induced lung tumorigenesis. Cancer Prev Res (Phila). Sep 2010;3(9):1066-1076.
73. Lai SW, Liao KF, Chen PC, Tsai PY, Hsieh DP, Chen CC. Antidiabetes drugs correlate with decreased risk of lung cancer: a population-based observation in Taiwan. Clin Lung Cancer. Mar 2012;13(2): 143-148.
74. van der MT. Co-morbidities of COPD in primary care: frequency, relation to COPD, and treatment consequences. Prim Care Respir J. Dec 2010;19(4):326-334.
75. Poeggeler B, Saarela S, Reiter RJ, et al. Melatonin - a highly potent endogenous radical scavenger and electron donor: new aspects of the oxidation chemistry of this indole accessed in vitro. Ann N Y Acad Sci. November 17, 1994;738:419-420.
76. Anisimov VN, Zavarzina NY, Zabezhinski MA, et al. Melatonin increases both life span and tumor incidence in female CBA mice. J Gerontol A Biol Sci Med Sci. Jul 2001;56(7):B311-B323.
77. Anisimov VN, Alimova IN, Baturin DA, et al. Dose-dependent effect of melatonin on life span and spontaneous tumor incidence in female SHR mice. Exp Gerontol. Apr 2003;38(4):449-461.
78. Sharman EH, Sharman KG, Ge YW, Lahiri DK, Bondy SC. Age-related changes in murine CNS mRNA gene expression are modulated by dietary melatonin. J Pineal Res. Apr 2004;36(3):165-170.
79. Anisimov VN, Popovich IG, Zabezhinski MA, Anisimov SV, Vesnushkin GM, Vinogradova IA. Melatonin as antioxidant, geropro-tector and anticarcinogen. Biochim Biophys Acta. May 2006;1757(5-6): 573-589.
80. Gumral N, Naziroglu M, Ongel K, et al. Antioxidant enzymes and melatonin levels in patients with bronchial asthma and chronic obstruc-tive pulmonary disease during stable and exacerbation periods. Cell Biochem Funct. Jul 2009;27(5):276-283.
81. de Matos Cavalcante AG, de Bruin PFC, de Bruin VMS, et al. Melatonin reduces lung oxidative stress in patients with chronic obstrutive pul-monary disease: a randomized, double-blind, placebo-controlled study. Journal of Pineal Research. 2012;no.
82. Rodella LF, Favero G, Rossini C, et al. Aging and vascular dysfunction: beneficial melatonin effects. Age (Dordr). November 23, 2011.
83. Kim GD, Lee SE, Kim TH, Jin YH, Park YS, Park CS. Melatonin suppresses acrolein-induced IL-8 production in human pulmonary fibroblasts. J Pineal Res. Apr 2012;52(3):356-364.
84. Mishra A, Paul S, Swarnakar S. Downregulation of matrix metalloproteinase-9 by melatonin during prevention of alcohol-induced liver injury in mice. Biochimie. May 2011;93(5):854-866.
85. de la Lastra CA, Villegas I. Resveratrol as an antioxidant and pro-oxidant agent: mechanisms and clinical implications. Biochem Soc Trans. Nov 2007;35(Pt 5):1156-1160.
86. Knutson MD, Leeuwenburgh C. Resveratrol and novel potent activa-tors of SIRT1: effects on aging and age-related diseases. Nutr Rev. Oct 2008;66(10):591-596.
87. Frojdo S, Cozzone D, Vidal H, Pirola L. Resveratrol is a class IA phosphoinositide 3-kinase inhibitor. Biochem J. September 15, 2007; 406(3):511-518.
88. Centeno-Baez C, Dallaire P, Marette A. Resveratrol inhibition of inducible nitric oxide synthase in skeletal muscle involves AMPK but not SIRT1. Am J Physiol Endocrinol Metab. Nov 2011;301(5): E922-E930.
89. Donnelly LE, Newton R, Kennedy GE, et al. Anti-inflammatory effects of resveratrol in lung epithelial cells: molecular mechanisms. Am J Physiol Lung Cell Mol Physiol. Oct 2004;287(4):L774-L783
90. Babar P, Adamson C, Walker GA, Walker DW, Lithgow GJ. P13- kinase inhibition induces dauer formation, thermotolerance and longevity in C. elegans. Neurobiol Aging. Sep 1999;20(5):513-519.
91. Moskalev AA, Shaposhnikov MV. Longevity extension by specific inhibition of pI3K in Drosophila melanogaster. Adv Gerontol. 2008; 21(4):602-606.
92. To Y, Ito K, Kizawa Y, et al. Targeting Phosphoinositide-3-kinase-{delta} with Theophylline Reverses Corticosteroid Insensitivity COPD. Am J Respir Crit Care Med. March 11, 2010.
93. Moonen HJ, Geraets L, Vaarhorst A, Bast A, Wouters EF, Hageman GJ. Theophylline prevents NAD+ depletion via PARP-1 inhibition in human pulmonary epithelial cells. Biochem Biophys Res Commun. December 30, 2005;338(4):1805-1810.
94. Bjedov I, Partridge L. A longer and healthier life with TOR down-regulation: genetics and drugs. Biochem Soc Trans. Apr 2011;39(2): 460-465.
95. Morselli E, Maiuri MC, Markaki M, et al. The life span-prolonging effect of sirtuin-1 is mediated by autophagy. Autophagy. Jan 2010; 6(1):186-188.
96. Lee JS, Park KY, Min HG, et al. Negative regulation of stress-induced matrix metalloproteinase-9 by Sirt1 in skin tissue. Exp Dermatol. Dec 2010;19(12):1060-1066.
97. Borra MT, Smith BC, Denu JM. Mechanism of human SIRT1 activation by resveratrol. J Biol Chem. April 29, 2005;280(17): 17187-17195.
98. Milne JC, Lambert PD, Schenk S, et al. Small molecule activators of SIRT1 as therapeutics for the treatment of type 2 diabetes. Nature. November 29, 2007;450(7170):712-716.
99. Lee JS, Surh YJ. Nrf2 as a novel molecular target for chemoprevention. Cancer Lett. June 28, 2005;224(2):171-184.
100. Mukherjee S, Gangopadhyay H, Das DK. Broccoli: a unique vegetable that protects mammalian hearts through the redox cycling of the thi-oredoxin superfamily. J Agric Food Chem. January 23, 2008;56(2): 609-617.
101. Malhotra D, Thimmulappa RK, Mercado N, et al. Denitrosylation of HDAC2 by targeting Nrf2 restores glucocorticosteroid sensitiv-ity in macrophages from COPD patients. J Clin Invest. Nov 2011; 121(11):4289-4302.